Literature DB >> 10843719

Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production.

T Sugiura1, Y Kawaguchi, M Harigai, K Takagi, S Ohta, C Fukasawa, M Hara, N Kamatani.   

Abstract

In polymyositis (PM)/dermatomyositis (DM), T cells infiltrate the muscle tissues and interact with muscle cells via cell surface molecules. Recently, myoblasts have been reported to express CD40, but little is known about the role of CD40 in myoblasts. In the present study we examined the expression and involvement of CD40 and CD40 ligand (CD40L) in the interaction between muscle cells and T cells in PM/DM. Immunohistochemical staining revealed that CD40 was expressed on muscle cells in five of five PM and four of five DM patients, and that infiltrating mononuclear cells (MNCs) expressed CD40L in all cases of PM/DM. These CD40L-expressing MNCs were primarily CD4+ T cells. IFN-gamma, which is known to induce CD40 expression on various types of cells, was also expressed on the MNCs in four of the PM and four of the DM patients. Although cultured human myoblasts (SkMC 2859) did not express CD40 constitutively, IFN-gamma induced CD40 expression in a dose-dependent manner. To clarify the functional roles of CD40-mediated signals, the effects of a trimeric form of recombinant human CD40L on cytokine production were studied in SkMC 2859 that were prestimulated with IFN-gamma to express CD40. Recombinant human CD40L markedly increased the production of IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 of SkMC 2859. The expression of these humoral factors in muscle cells of PM and DM was demonstrated by immunohistochemistry. These results suggest that interaction between T cells and muscle cells via the CD40-CD40L system contributes to the immunopathogenesis of PM/DM by augmenting inflammation via cytokine production by the muscle cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843719     DOI: 10.4049/jimmunol.164.12.6593

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  Targeting CD40L: a promising therapeutic approach.

Authors:  Dimitris Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

2.  Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis.

Authors:  M Aleksza; A Szegedi; P Antal-Szalmás; B Irinyi; L Gergely; A Ponyi; J Hunyadi; S Sipka; M Zeher; G Szegedi; K Dankó
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

Review 3.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

4.  Role of CD40 in prion disease and the immune response to recombinant PrP.

Authors:  Richard Rubenstein; Allen Chiu; Binggong Chang; Thomas Wisniewski
Journal:  J Neuroimmunol       Date:  2013-02-16       Impact factor: 3.478

5.  CD40 is expressed and functional on neuronal cells.

Authors:  Jun Tan; Terrence Town; Takashi Mori; Demian Obregon; Yajuan Wu; Anthony DelleDonne; Amyn Rojiani; Fiona Crawford; Richard A Flavell; Mike Mullan
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

6.  Activation of osmolyte pathways in inflammatory myopathy and Duchenne muscular dystrophy points to osmoregulation as a contributing pathogenic mechanism.

Authors:  Boel De Paepe; Jean-Jacques Martin; Sandrine Herbelet; Cecilia Jimenez-Mallebrera; Estibaliz Iglesias; Cristina Jou; Joachim Weis; Jan L De Bleecker
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

7.  Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.

Authors:  Luca Bello; Kevin M Flanigan; Robert B Weiss; Pietro Spitali; Annemieke Aartsma-Rus; Francesco Muntoni; Irina Zaharieva; Alessandra Ferlini; Eugenio Mercuri; Sylvie Tuffery-Giraud; Mireille Claustres; Volker Straub; Hanns Lochmüller; Andrea Barp; Sara Vianello; Elena Pegoraro; Jaya Punetha; Heather Gordish-Dressman; Mamta Giri; Craig M McDonald; Eric P Hoffman
Journal:  Am J Hum Genet       Date:  2016-10-13       Impact factor: 11.025

8.  Premature labor: a state of platelet activation?

Authors:  Offer Erez; Roberto Romero; Debra Hoppensteadt; Jawed Fareed; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Nandor Gabor Than; Edi Vaisbuch; Chong Jai Kim; Jimmy Espinoza; Pooja Mittal; Neil Hamill; Chia-Ling Nhan-Chang; Moshe Mazor; Sonia Hassan
Journal:  J Perinat Med       Date:  2008       Impact factor: 1.901

9.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

10.  Acute resistance exercise increases the expression of chemotactic factors within skeletal muscle.

Authors:  Paul A Della Gatta; David Cameron-Smith; Jonathan M Peake
Journal:  Eur J Appl Physiol       Date:  2014-06-27       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.